Riverside Partners, a Boston-based private equity firm, is pleased to announce the completion of an investment in BioAgilytix Labs (BioAgilytix), a leading bioanalytical laboratory specializing in large molecular biologic drugs. The investment of Riverside Partners was completed in partnership with the BioAgilytix Founders and the Management Team.
Headquartered in Research Triangle Park, North Carolina, BioAgilytix provides outsourced laboratory services to customers in the pharmaceutical, biotechnology and agricultural industries. By developing, optimizing and conducting bioanalytical testing, the Company offers its customers a high-quality outsourcing option that supports drug discovery, pre-clinical and clinical development and manufacturing.
“The BioAgilytix team is very excited about working with Riverside Partners The Riverside team has a strong understanding of how to scale up the pharmaceutical services business, and both organizations have a very strong cultural fit,” said Jim Petrilla, co-founder and CEO of BioAgilytix.
“The co-founders of Jim Petrilla and Dr. Afshin Safavi has built a terrific business focused on supporting the development of large-scale molecular drugs, a very exciting area in the pharmaceutical and biotechnology industries. Riverside Partners is looking forward to using our deep healthcare experience to help accelerate the company’s growth,” said Philip Borden, General Partner at Riverside Partners.
About BioAgilytix Laboratories
BioAgilytix Labs is a specialized bioanalytical testing laboratory focused on large-scale molecular bioanalysis for the pharmaceutical, biotechnology and agricultural industries. The mission of BioAgilytix Lab is to provide outsourced analysis of biological samples that support the work of companies seeking regulatory approval of their biopharmaceutical and agricultural products. For more information on the Company, please visit
